Document:

Exhibit 10.5

 

PROMISSORY NOTE

 

	$200,000.00	As of September 9, 2014

 

CB Pharma Acquisition
Corp. (“Maker”) promises to pay to the order of Coronado Biosciences, Inc. (“Payee”) the principal sum
of Two Hundred Thousand Dollars and No Cents ($200,000.00) in lawful money of the United States of America, on the terms and conditions
described below. This Note supersedes and replaces all outstanding notes from Maker to Payee.

 

1.          Principal.
The principal balance of this Note shall be repayable on the earlier of (i) September 9, 2015, (ii) the date on which Maker consummates
an initial public offering of its securities (“IPO”) or (iii) the date on which Maker determines to not proceed with
such IPO.

 

2.          Interest.
No interest shall accrue on the unpaid principal balance of this Note.

 

3.          Application
of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due
under this Note, including (without limitation) reasonable attorneys’ fees, then to the payment in full of any late charges
and finally to the reduction of the unpaid principal balance of this Note.

 

4.          Events
of Default. The following shall constitute Events of Default:

 

(a)          Failure
to Make Required Payments. Failure by Maker to pay the principal of this Note within five (5) business days following the date
when due.

 

(b)          Voluntary
Bankruptcy, Etc. The commencement by Maker of a voluntary case under the Federal Bankruptcy Code, as now constituted or hereafter
amended, or any other applicable federal or state bankruptcy, insolvency, reorganization, rehabilitation or other similar law,
or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator
(or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the
benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action
by Maker in furtherance of any of the foregoing.

 

(c)          Involuntary
Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of maker
in an involuntary case under the Federal Bankruptcy Code, as now or hereafter constituted, or any other applicable federal or state
bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or
similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs,
and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

 

    	 

    	 

    

 

5.          Remedies.

 

(a)          Upon
the occurrence of an Event of Default specified in Section 4(a), Payee may, by written notice to Maker, declare this Note to be
due and payable, whereupon the principal amount of this Note, and all other amounts payable thereunder, shall become immediately
due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything
contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

(b)          Upon
the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of, and all other sums
payable with regard to, this Note shall automatically and immediately become due and payable, in all cases without any action on
the part of Payee.

 

6.          Waivers.
Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor,
protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by
Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting
any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or
sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and
Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution
issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

7.          Unconditional
Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement
of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other
party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or
consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted
by Payee with respect to the payment or other provisions of this Note, and agree that additional makers, endorsers, guarantors,
or sureties may become parties hereto without notice to them or affecting their liability hereunder.

 

8.          Notices.
Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt requested, (ii) personally
delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery,
(iv) sent by telefacsimile or (v) sent by e-mail, to the following addresses or to such other address as either party may designate
by notice in accordance with this Section:

 

If to Maker:

 

CB Pharma Acquisition Corp.

24 New England Executive Park, Suite 105

Burlington, MA 01803

 

    	2

    	 

    

 

If to Payee:

 

Coronado Biosciences, Inc.

24 New England Executive Park,
Suite 105

Burlington, MA 01803

 

Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a telefacsimile transmission confirmation,
(iii) the date on which an e-mail transmission was received by the receiving party’s on-line access provider (iv) the date
reflected on a signed delivery receipt, or (vi) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.

 

9.          Construction.
This Note shall be construed and enforced in accordance with the domestic, internal law, but not the law of conflict of laws, of
the State of New York.

 

10.         Severability.
Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any
such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other
jurisdiction.

 

IN WITNESS WHEREOF,
Maker, intending to be legally bound hereby, has caused this Note to be duly executed by its Chief Executive Officer the day and
year first above written.

 

	 	CB PHARMA ACQUISITION CORP.
	 	 	 	 
	 	By:	 	 
	 	 	Name:  Lindsay A. Rosenwald, M.D.
	 	 	Title: Chief Financial Officer

 

    	3Exhibit 10.1

 

October 20, 2014

 

Mr. Scott R. Silverman

Chief Executive Officer

VeriTeQ Corporation

220 Congress Park Drive, Suite 200

Delray Beach, FL 33445

 

GLUCOCHIP
AND SETTLEMENT AGREEMENT

 

Dear Mr. Silverman:

 

This GlucoChip
and Settlement Agreement (the “Agreement”) is intended to document the agreement between PositiveID Corporation (“PSID”)
and VeriTeQ Corporation and its subsidiaries (“VTEQ”) (collectively, the “Parties”) and is intended to
be contractually binding on both Parties. The Parties intend to transfer the rights to the GlucoChip intellectual property from
PSID to VTEQ, with a commitment by PSID to support VTEQ’s development program of the GlucoChip intellectual property for
a period of up to two years. The terms of this Agreement are as follows:

 

		1.	GlucoChip
– As of this date, the License Agreement, dated August 28, 2012 between PSID and VTEQ
will be terminated and PSID’s sole right to any future benefit (royalty) of GlucoChip or any other implantable bio sensor
application shall be as set forth in the Asset Purchase Agreement dated August 28, 2012 between VeriTeQ Acquisition Corporation
and PSID.

		2.	Immediate
Financial Support - PSID will provide a loan to VTEQ, at closing of this Agreement, of $60,000. 
The form of the loan will be a convertible promissory note. The terms of the note are set forth in a Convertible Promissory Note
dated October 20, 2014 set forth as Schedule A attached hereto (“Note 1”).

		3.	Ongoing
Financial Support – Through October 20, 2016 PSID will provide continuing support
to VTEQ in furtherance of the VTEQ development of its implantable bio sensor applications.  PSID will provide VTEQ with an
additional $40,000 convertible promissory note on the same terms and conditions as Note 1 within one hundred (100) days after
the closing of this Agreement. Thereafter, at intervals of one hundred (100) days, PSID and VTEQ will enter into a new convertible
promissory note of $50,000 on the same terms as condition as Note 1 (”Additional Notes”). In the event the share reserve
requirements of either the warrant (see #4 below) or any then outstanding note(s) is not met, PSID is not obligated to enter into
any new notes. At any time prior to October 20, 2016, VTEQ, at its sole discretion, may inform PSID in writing, at least ten (10)
days prior to an ongoing support payment that it does not desire to have such payment made.

 

1690
South Congress Avenue · Suite
201 · Delray Beach, Florida 33445

Telephone:
561.805.8000 · Fax: 561.805.8001

 

    	 

    	 

    

 

Exhibit 10.1

 

		4.	Common
Share Reserves – PSID currently holds a Warrant Agreement from VTEQ, dated November
13, 2013. VTEQ agrees to provide an irrevocable reserve letter to its transfer agent for 10,000,000 shares of common stock under
the warrant. Further, VTEQ agrees as soon as possible, to provide additional irrevocable reserves covering at least 2X the number
of shares that would be due if the warrant were exercised in full and to increase the share reserve to maintain that level at
any time requested by PSID, but not more than once a month. If at any time a warrant reserve is not met, PSID will have no further
obligation to provide any funding pursuant to the Additional Notes. In the event that VTEQ does not provide the irrevocable reserves
for the Warrant or either of the Notes attached hereto by December 15, 2014, the 100 day intervals for new notes will be extended
by one day for each day after December 15, 2014 until the irrevocable reserves are ultimately established. So long at the reserve
requirements of the warrant and any notes are met, PSID will never convert any amount of shares that would have it exceed a 9.99%
ownership in VTEQ.

		5.	Payment
of Shared Services Agreement - VTEQ currently owes PSID $222,115.07 pursuant to the Shared
Services Agreement, between PSID and VTEQ, dated January 11, 2012, as amended. This outstanding amount will be paid at closing
by issuing a convertible promissory note, as documented in the Convertible Promissory Note dated October 20, 2014 (in the principal
amount of $222,115.07) as set forth on Schedule A attached hereto.

		6.	Miscellaneous
– Governing law for this Agreement will be Florida and if there are any conflicting
terms in any other agreements between the Parties, the terms of this Agreement will govern.

 

By signing
this Agreement, PSID and VTEQ agree to the terms above as of October 20, 2014.

 

Sincerely,

 

William J. Caragol

Chief Executive Officer

 

Acknowledged and Agreed:

 

VERITEQ CORPORATION

 

	By:	 /s/ Scott Silverman	 
	Name:   Scott R. Silverman 	 
	Title:    Chief Executive Officer	 

 

1690
South Congress Avenue · Suite
201 · Delray Beach, Florida 33445

Telephone:
561.805.8000 · Fax: 561.805.8001

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]